RESUMEN
In the healthcare area of Santiago de Compostela (Spain), the therapeutic subgroup "other antipsychotics" represented the fifth largest outpatient expenditure in 2013. More than half of this expenditure corresponded to long-acting parenteral forms of paliperidone and risperidone. Over a 12-month period, the implementation of a pharmaceutical care program based on process management and coordination of actions between health professionals in both levels of care represented savings of 636,391.01 for the organization and a direct saving of 16,767.36 and 9,008 trips to the pharmacy for patients. This study shows the efficiency of the program, which was facilitated by its situation in an area of integrated management and the use the unified medical records and electronic prescription, elements that will enable the future implementation of similar programmes. The new registries and healthcare interventions will allow reliable evaluation of their effectiveness in terms of treatment adherence, relapses and hospitalisations.
Asunto(s)
Antipsicóticos/uso terapéutico , Prestación Integrada de Atención de Salud/organización & administración , Servicios Farmacéuticos/organización & administración , Antipsicóticos/administración & dosificación , Antipsicóticos/economía , Antipsicóticos/farmacocinética , Áreas de Influencia de Salud , Ahorro de Costo , Análisis Costo-Beneficio , Preparaciones de Acción Retardada , Eficiencia Organizacional , Prescripción Electrónica , Humanos , Inyecciones , Palmitato de Paliperidona/administración & dosificación , Palmitato de Paliperidona/economía , Palmitato de Paliperidona/farmacocinética , Palmitato de Paliperidona/uso terapéutico , Pautas de la Práctica en Medicina , Honorarios por Prescripción de Medicamentos , Risperidona/administración & dosificación , Risperidona/economía , Risperidona/farmacocinética , Risperidona/uso terapéutico , EspañaRESUMEN
BACKGROUND: Atypical antipsychotics have similar clinical efficacy in the treatment of schizophrenia; variability in their tolerability represents the discerning factor in treatment choices. Sertindole has a relatively good tolerability profile that favours long-term patient adherence and, therefore, is associated with lower rates of relapse and rehospitalization. AIM: A model was developed to compare the cost-effectiveness of a 5-year treatment strategy starting with sertindole versus olanzapine, risperidone, aripiprazole or the typical antipsychotic agent, haloperidol. METHODS: The model was based on published trials and local clinical practice, and considered costs from the perspective of the Swedish National Health Insurance Board. RESULTS: All atypical agents were clinically superior and more cost-effective than haloperidol with a cost per quality-adjusted life year gained of approximately 490,000 Swedish kroner. Sertindole was associated with the lowest direct and indirect medical costs, driven by its tolerability profile. CONCLUSIONS: Sertindole represents a useful alternative to the current treatment options available in Sweden. CLINICAL IMPLICATIONS: The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs. Sertindole appears to be a clinically and cost-effective alternative in the management of patients with schizophrenia in Sweden.
Asunto(s)
Antipsicóticos/economía , Imidazoles/economía , Indoles/economía , Esquizofrenia/tratamiento farmacológico , Adulto , Antipsicóticos/uso terapéutico , Aripiprazol , Benzodiazepinas/economía , Benzodiazepinas/uso terapéutico , Análisis Costo-Beneficio , Economía Farmacéutica , Femenino , Haloperidol/economía , Haloperidol/uso terapéutico , Humanos , Imidazoles/uso terapéutico , Indoles/uso terapéutico , Masculino , Modelos Económicos , Programas Nacionales de Salud , Olanzapina , Piperazinas/economía , Piperazinas/uso terapéutico , Quinolonas/economía , Quinolonas/uso terapéutico , Risperidona/economía , Risperidona/uso terapéutico , SueciaRESUMEN
Second-generation atypical antipsychotics such as clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride and ariprazole offer the potential to reduce the significant health care resource demands in the treatment of schizophrenia through improved levels of initial clinical response and reduced levels of long-term acute relapse. However, the optimal sequencing of these drugs remains unclear. To consider this issue from a health economic viewpoint a decision model approach was used comparing healthcare costs and clinical outcomes when treating patients with alternative sequences of atypical antipsychotic treatment. Treated patients were assumed to be in a current acute episode with at least a 10-year history of disease and to be naive to previous atypical treatments. Treatment strategies were based on either first-line olanzapine or risperidone with switching to the alternative drug as second-line treatment following an inadequate clinical response to first-line drug therapy. Clinical response data were derived from a pivotal published comparative study of both olanzapine and risperidone. Published data on the long-term use of antipsychotic drugs where used wherever possible to populate the model for relapse rates during the maintenance phase. Health care resource data were defined for Germany based on expert clinical opinion. A treatment strategy of first-line olanzapine was shown to be cost saving over a 1-year period, with additional clinical benefits in the form of avoided relapses. The model suggests that over the first year of treatment a strategy of first-line olanzapine is associated with lower risk of additional relapse (0.33 fewer acute relapses per 100 patients per year) and with cost savings (euro 35,306 per 100 patients per year). There is a need for longer term direct in-trial comparisons of atypical antipsychotics to confirm these indicative results.
Asunto(s)
Antipsicóticos/economía , Técnicas de Apoyo para la Decisión , Costos de la Atención en Salud , Risperidona/economía , Esquizofrenia/economía , Antipsicóticos/uso terapéutico , Benzodiazepinas/economía , Benzodiazepinas/uso terapéutico , Alemania , Hospitalización/economía , Humanos , Olanzapina , Años de Vida Ajustados por Calidad de Vida , Recurrencia , Risperidona/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/prevención & control , Resultado del Tratamiento , Prevención del SuicidioRESUMEN
This study assessed differences in total mental health care costs for 1 year following initiation of risperidone or olanzapine in individuals within NorthSTAR, an integrated managed mental health pilot project. A retrospective database analysis of individuals with schizophrenia or schizoaffective disorder and newly started on either agent was conducted. Antipsychotic medication costs were significantly lower for individuals prescribed risperidone than olanzapine (1763 dollars versus 2582 dollars; p<0.001). Individuals prescribed risperidone had lower (but not significant) expenditures for mental health services (4714 dollars versus 5077 dollars; p=0.792), as well as total mental health care costs (7407 dollars versus 9011 dollars; p=0.255).
Asunto(s)
Antipsicóticos/economía , Servicios de Salud Mental , Risperidona/economía , Benzodiazepinas/economía , Prestación Integrada de Atención de Salud , Costos de los Medicamentos , Olanzapina , Estudios Retrospectivos , Esquizofrenia/tratamiento farmacológico , TexasRESUMEN
Improved drug therapy for schizophrenia may represent the best strategy for reducing the costs of schizophrenia and the recurrent chronic course of the disease. Olanzapine and risperidone are atypical antipsychotic agents developed to meet this need. We report a multicenter, double-blind, parallel, 30-week study designed to compare the efficacy, safety, and associated resource use for olanzapine and risperidone in Australia and New Zealand. The study sample consisted of 65 patients who met DSM-IV criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder. Olanzapine-treated patients showed a significantly greater reduction in Positive and Negative Syndrome Scale (PANSS) total, Brief Psychiatric Rating Scale (BPRS) total, and PANSS General Psychopathology scores at endpoint compared to the risperidone-treated patients. Response rates through 30 weeks showed a significantly greater proportion of olanzapine-treated patients had achieved a 20% or greater improvement in their PANSS total score compared to risperidone-treated patients. Olanzapine and risperidone were equivalent in their improvement of PANSS positive and negative scores and Clinical Global Impression-Severity of Illness scale (CGI-S) at endpoint. Using generic and disease-specific measures of quality of life, olanzapine-treated patients showed significant within-group improvement in most measures, and significant differences were observed in favor of olanzapine over risperidone in Quality of Life Scale (QLS) Intrapsychic Foundation and Medical Outcomes Study Short Form 36-item instrument (SF-36) Role Functioning Limitations-Emotional subscale scores. Despite the relatively small sample size, our study suggests that olanzapine has a superior risk:benefit profile compared to risperidone.